Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

This setup supports only a cautious YES estimate. The study is Phase 2, nonrandomized, uncontrolled, and open-label, so any efficacy claim rests on cross-trial comparisons rather than an internal control. That is especially challenging in a heterogeneous population spanning esophageal, GEJ, pancreatic, and other advanced solid tumors, where baseline response expectations and prognosis differ materially. The primary endpoint is investigator-assessed ORR, which is a practical Phase 2 readout and can generate an early signal, but it is softer than blinded review or time-to-event outcomes and is more vulnerable to optimism in an open-label setting. Combination therapy can lift response rates, yet it also muddies attribution because the PD-1-based standard-of-care backbone already has activity. For a result to read clearly positive, ORR likely needs to look meaningfully better than historical experience while remaining tolerable. With primary completion just passed and the study still active, operational timing risk seems modest but not zero. Overall, this looks slightly more likely to disappoint than to produce a clearly positive readout.

This Phase 2 single-arm trial tests futibatinib + pembrolizumab + SOC chemo in treatment-naïve esophageal and pancreatic cancer patients, with ORR as the primary endpoint. The phase 1b predecessor showed a very promising 68.4% ORR in the first-line EC cohort (COD), well above the ~45% ORR seen with pembrolizumab + chemo alone in KEYNOTE-590. However, several factors create substantial uncertainty: (1) the phase 1b COD was very small and in Japanese patients (potential population bias); (2) the pancreatic cancer cohort is far more challenging with generally low ORR expectations for any regimen; (3) futibatinib is an FGFR inhibitor being tested in an unselected (non-FGFR-selected) population, which reduces the mechanistic rationale; (4) adding a TKI to chemo+ICI increases toxicity risk potentially compromising dose intensity; (5) the trial is past primary completion but no results have been disclosed yet. The positive signal in EC is offset by likely poor performance in pancreatic cancer. The definition of 'positive results' for an uncontrolled Phase 2 is ambiguous. Overall probability is roughly a coin flip.

This is a Phase 2 uncontrolled study evaluating futibatinib (FGFR inhibitor) plus PD-1-based chemo in multiple solid tumors. Phase 2 oncology trials historically have ~30-40% success rates. The combination approach adds complexity - while FGFR inhibitors have shown activity in FGFR-altered cancers, the broad solid tumor population (esophageal, pancreatic, GEJ) includes heterogeneous生物学. The uncontrolled, non-randomized design means 'positive' requires meeting a pre-specified ORR threshold, which is challenging to achieve given variability across tumor types. The trial has passed primary completion (-32 days), so data likely exists. However, the multi-arm combination (futibatinib + pembrolizumab + cisplatin + 5-FU) creates toxicity and efficacy interpretation challenges. Given the indication breadth and uncontrolled nature, intrinsic probability of clear positive outcome is modest, below 50%.

This is a nonrandomized, uncontrolled Phase 2 basket trial in heterogeneous, late-line solid tumors, a notoriously challenging setting for efficacy signals. The primary endpoint is objective response rate (ORR), a direct but high-variance measure. Futibatinib, an FGFR inhibitor, combined with a PD-1 antibody and cytotoxic chemotherapy, creates a complex, potentially toxic regimen. The trial completed primary data collection 32 days ago, indicating imminent results. The lack of a control arm and the aggressive tumor types suggest a low intrinsic probability of a definitively 'positive' result, though a signal is possible. Operational risk is low as recruitment is finished.

Open-label, nonrandomized Phase 2 trial tests futibatinib (FGFR inhibitor) + PD-1 (pembrolizumab) + SoC chemo (cisplatin/5-FU) in unresectable/metastatic esophageal (adeno/squamous), Siewert 1 GEJ, and pancreatic cancers. Primary endpoint: investigator-assessed ORR (RECIST 1.1) at 12 months, prone to bias without blinding/control arm. Heterogeneous population with poor prognosis; FGFR alterations actionable in some esophageal/GEJ but rarer in pancreatic—efficacy hinges on unclear biomarker selection (futibatinib monotherapy ~40% ORR in FGFR+ cholangioca priors, modest otherwise). SoC PD-1+chemo ORR benchmarks ~30-45% in esophageal, so positivity requires combo exceeding ~35-40% threshold. Taiho solid operational history, multicenter design feasible. Trial overdue 32 days past primary completion (status active, not recruiting), signals disclosure risk if immature/negative data. Overall, endpoint softness, selection uncertainty yield ~45% chance of positive ORR result.

The Phase 2 trial (NCT05945212) evaluates futibatinib plus pembrolizumab in esophageal and pancreatic cancers. The single-arm, open-label design introduces bias. The combination of a FGFR inhibitor with a PD-1 inhibitor is mechanistically sound but faces significant clinical risk. Prior futibatinib data shows activity, but the combination with pembrolizumab in a heavily pre-treated population carries a substantial risk of toxicity-related discontinuations. Given the single-arm design, the bar for success is lower, but the probability of a clinically meaningful ORR in these late-line patients is estimated at only 35%.

This Phase 2 basket trial tests futibatinib (FGFR2 inhibitor) plus PD-1-based therapy in advanced solid tumors with FGFR2 alterations. Primary completion was March 2026 (32 days past), suggesting data lock or imminent readout. The design is non-randomized, single-arm, open-label—no control arm, which inflates apparent efficacy risk. ORR endpoint at 12 months is reasonable but investigator-assessed (not blinded), adding bias risk. The tumor mix (esophageal, pancreatic, GEJ) are historically immunotherapy-resistant settings; adding an FGFR2 inhibitor has mechanistic rationale but unproven synergy. Prior futibatinib monotherapy showed modest activity in cholangiocarcinoma (20% ORR). Combination toxicity (FGFR2 inhibition + chemo + PD-1) could limit dose intensity. Disclosure risk is elevated given past-due completion date—results could drop imminently. Overall, single-arm design in difficult indications with open-label assessment tilts toward skepticism.

This Phase 2 open-label trial evaluates the combination of futibatinib (an FGFR inhibitor), pembrolizumab, and standard-of-care chemotherapy in first-line, unselected patients with esophageal (Cohort A) and pancreatic (Cohort B) cancers. The primary endpoint is investigator-assessed Objective Response Rate (ORR) within 12 months. The intrinsic probability of a positive trial rests heavily on prior Phase 1b results (presented at ESMO 2023), which investigated this exact combination in first-line esophageal carcinoma. That study demonstrated a highly encouraging 68.4% ORR, which compares favorably to the ~45% ORR historical benchmark for standard chemo-immunotherapy (e.g., KEYNOTE-590). While the Phase 1b sample size was small, the large efficacy buffer provides significant cushion against regression to the mean in this expanded Phase 2 cohort. Additionally, the use of investigator-assessed ORR rather than blinded independent central review typically results in slightly more favorable response grading. The primary risks involve cumulative toxicity—especially in the pancreatic cohort receiving the aggressive mFOLFIRINOX backbone—which could prompt dose interruptions that compromise efficacy. However, since trial success generally requires only one cohort to clear its pre-specified hurdle, the strong biological and empirical signal in the esophageal cohort drives a favorable outlook. I estimate a 70% probability of a positive outcome.

The trial is a Phase 2 study evaluating the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based standard of care therapy in adult patients with solid tumors. The primary endpoint is ORR by investigator assessment. Given the Phase 2 nature, the study is not yet fully powered for a definitive outcome. However, the combination of futibatinib with PD-1 inhibitors has a rationale based on potential synergistic effects. The current status is Active Not Recruiting, and the primary completion date is near. While there is a scientific rationale for the combination, the probability of a positive result is not high enough to warrant a strong confidence call at this stage.